Drilldown: Medicines
Use the filters below to narrow your results.
generic:
brand:
classes: (Click arrow to add another value)
mechanism:
None (2) ·
Central and peripheral COMT inhibitor (1) ·
D1/D2/D3 receptor agonist (1) ·
D2 agonist; D1 partial agonist (1) ·
D2 receptor agonist (1) ·
Dopamine precursor (1) ·
Dopamine precursor + DOPA decarboxylase inhibitor (1) ·
Extremely potent GABAA positive allosteric modulator (1) ·
GABAA positive allosteric modulator (15) ·
GABAA positive allosteric modulator (non-benzodiazepine) (3) ·
GABAA positive allosteric modulator; very long half-life (1) ·
GABAA potentiator (1) ·
GABAA potentiator and direct activator (2) ·
GABAB agonist; GHB receptor agonist (1) ·
Humanized IgG1 monoclonal antibody binding CGRP peptide; IV infusion enables fastest onset of any CGRP mAb (1) ·
Humanized IgG2 monoclonal antibody binding both isoforms of CGRP peptide (1) ·
Humanized IgG4 monoclonal antibody binding CGRP peptide; prevents CGRP from activating its receptor (1) ·
Irreversible selective MAO-B inhibitor (2) ·
MAO-B inhibitor; sodium channel blocker; glutamate release inhibitor (1) ·
Melatonin receptor agonist (2) ·
Muscarinic receptor antagonist (1) ·
Muscarinic receptor antagonist; dopamine reuptake inhibitor (1) ·
NMDA antagonist; dopamine releasing agent (1) ·
Non-selective dopamine receptor agonist (1) ·
Once-daily COMT inhibitor (1) ·
Peripheral COMT inhibitor (1) ·
Positive allosteric modulator of the GABA<sub>A</sub> receptor at the benzodiazepine binding site; increases frequency of Cl<sup>−</sup> channel opening, producing anxiolytic, sedative, hypnotic, anticonvulsant, and skeletal-muscle relaxant effects. (1) ·
Selective GABAA agonist (extrasynaptic delta subunit) (1) ·
Selective M1 muscarinic antagonist (1)
uses:
None (45) ·
No approved medical problem. Encountered as a designer/research benzodiazepine and, increasingly, as an adulterant in illicit opioid supplies. (1) ·
Preventive treatment of migraine in adults (1) ·
Preventive treatment of migraine in adults (episodic and chronic) (1) ·
Preventive treatment of migraine in adults; episodic cluster headache (1)
starting dose:
None (45) ·
100 mg IV every 3 months; may increase to 300 mg IV every 3 months (1) ·
225 mg SC monthly, or 675 mg SC every 3 months (quarterly) (1) ·
Migraine: 240 mg SC loading dose, then 120 mg SC monthly. Cluster: 300 mg SC at onset of cluster period, then monthly during cluster. (1) ·
No medical dose. Active recreational doses reported in the 0.5–1.5 mg range (similar potency to alprazolam). (1)
preparations:
fda max:
routes:
onset:
duration:
halflife:
bioavailability:
pregnancy:
Showing below up to 49 results in range #1 to #49.